New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
10:24 EDTCLVSClovis volatility elevated
Clovis April call option implied volatility is at 78, May is at 86, July is at 76; compared to its 26-week average of 72 according to Track Data suggesting larger near term price movement.
News For CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 22, 2015
08:03 EDTCLVSClovis names Dr. Lindsey Rolfe as Chief Medical Officer
Clovis Oncology announced that Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, has been named Chief Medical Officer and EVP of Clinical and Preclinical Development and Pharmacovigilance, to become effective in early August. Dr. Rolfe succeeds Dr. Andrew Allen, who will be stepping down from his role at Clovis at that time to create a new immuno-oncology focused biotechnology company and serve as its CEO. Dr. Rolfe joined Clovis in early 2010 and oversees rociletinib and rucaparib development in her current role as SVP of Clinical Development. As Chief Medical Officer at Clovis, Dr. Rolfe will be responsible for clinical development, preclinical development, clinical operations and pharmacovigilance and will also serve on the company’s executive committee.
June 15, 2015
08:06 EDTCLVSClovis price target raised to $115 from $85 at WallachBeth
WallachBeth analyst Bob Ai raised his raised for shares of Clovis Oncology (CLVS) to $115 from $85 and recommends using the recent pullback as a buying opportunity. Ai finds it inappropriate to directly compare the clinical data for Clovis's Rociletinib to AstraZeneca's (AZN) lung cancer drug AZD9291 due to differences in patients enrolled. He says not all news from ASCO 2015 is bad for Clovis and keeps a Buy rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use